Loomis, Sayles & Company
INBX

Loomis, Sayles & Company’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Loomis, Sayles & Company’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,082,225
Closed -$41.1M – 1013
2023
Q4 		$41.1M Sell
1,082,225
-34,259
-3% -$734K 0.06% 144
2023
Q3 		$20.5M Sell
1,116,484
-34,847
-3% -$729K 0.04% 238
2023
Q2 		$29.9M Sell
1,151,331
-10,651
-0.9% -$249K 0.05% 190
2023
Q1 		$21.9M Buy
1,161,982
+161,176
+16% +$3.75M 0.04% 223
2022
Q4 		$24.7M Sell
1,000,806
-23,938
-2% -$704K 0.05% 198
2022
Q3 		$18.4M Sell
1,024,744
-11,551
-1% -$208K 0.04% 220
2022
Q2 		$11.8M Sell
1,036,295
-4,120
-0.4% -$60.6K 0.02% 335
2022
Q1 		$23.2M Buy
+1,040,415
New +$26.6M 0.03% 268

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Loomis, Sayles & Company's INBX Position: Q1 2024 in Review

Loomis, Sayles & Company sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2024, closing a stake of 1,082,225 shares — an estimated $41.1M sold.

Loomis, Sayles & Company first reported a position in INBX in Q1 2022 and held it in 8 quarters. The position peaked at $41.1M in Q4 2023. 126 funds tracked by Wall St. Rank hold INBX as of Q1 2024.

  • Loomis, Sayles & Company reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Loomis, Sayles & Company sold 1,082,225 Inhibrx, Inc. Common Stock shares in Q1 2024, an estimated $41.1M.
  • Loomis, Sayles & Company first reported a position in Inhibrx, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
  • Loomis, Sayles & Company's Inhibrx, Inc. Common Stock position peaked at $41.1M in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2024.

Based on Loomis, Sayles & Company's 13F filing for Q1 2024, filed 14 May 2024.